Pfizer: EU approves 'precision drug' for breast cancer

(CercleFinance.com) - The European Commission has approved Pfizer's Talzenna as monotherapy for the treatment of patients with inherited BRCA-mutated locally advanced or metastatic breast cancer, the US drugmaker said.


Pfizer said the once-daily, alternative treatment to chemotherapy is part of its "precision medicine approach" to drug development.

In a phase III trial, Talzenna reduced the risk of disease progression by 46% and more than doubled the overall response rate compared to chemotherapy, it said.

This approval follows approval by the US Food and Drug Administration (FDA) in October 2018, Pfizer said.

Copyright (c) 2019 CercleFinance.com. All rights reserved.